Results 151 to 160 of about 65,744 (296)
Prevalence of function‐limiting late effects in survivors of head and neck cancer
PM&R, Volume 17, Issue 6, Page 654-662, June 2025.Abstract Background Survivors of head and neck cancer (HNC) are commonly affected by multiple complex and interrelated long‐term and late effects that can adversely affect their function and quality of life. Objective To define the prevalence of neuromuscular, musculoskeletal, visceral, oncologic, and other late effects affecting function and quality ...
Yu Hui Won, Michael D. Stubblefield
wiley +1 more source
Summary of Panel on Management of Myelopathy and Radiculopathy of Cervical Spondylosis [PDF]
, 1977 Stewart B. Dunsker
openalex +1 more source
Myelopathy due to spinal metastasis from adenocarcinoma of the gallbladder [PDF]
, 1977 Richard P. Newman +2 more
openalex +1 more source
Myelopathy associated with Systemic Lupus Erythematosus (Erythema Nodosum) [PDF]
, 1978 L S Kewalramani +2 more
openalex +1 more source
European Journal of Neurology, Volume 32, Issue 6, June 2025.ABSTRACT Background Cortical hyperexcitability is an early feature of amyotrophic lateral sclerosis (ALS), linked to dysfunction in inhibitory and facilitatory cortical circuits, measurable using paired‐pulse transcranial magnetic stimulation (TMS). Short‐interval intracortical inhibition (SICI) is a robust biomarker of inhibitory function and an ALS ...
Cláudia Santos Silva +6 more
wiley +1 more source
European Journal of Neurology, Volume 32, Issue 6, June 2025.Plasma peripherin (PRPH) levels are significantly elevated in patients with motor neuron diseases (MND), including ALS, compared to both MND mimics and healthy controls. Higher baseline PRPH correlates with better functional status, slower disease progression, and longer survival, suggesting it may reflect an endogenous motor neuron injury response ...
Alessandro Bombaci +7 more
wiley +1 more source
Headache: The Journal of Head and Face Pain, Volume 65, Issue 6, Page 1005-1014, June 2025.Abstract Objective To evaluate the safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine (EM). Background Atogepant is an oral calcitonin gene‐related peptide (CGRP) receptor antagonist approved for the preventive treatment of migraine in adults and ...
Jessica Ailani +9 more
wiley +1 more source
Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 6, Page 1174-1184, June 2025.Patients with alopecia areata received etrasimod 2 mg, 3 mg or placebo oncedaily for 24 weeks, followed by a 28‐week open‐label extension period. Overall, etrasimod 2 mg and 3 mg were safe and well tolerated in patients; their efficacy was numerically higher than placebo and appeared to be dose dependent.
B. King +5 more
wiley +1 more source